BL-M17D1

Phase 1Small molecule

BL-M17D1 is one of 86 small molecule programs targeting Advanced or Metastatic Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Metastatic Solid TumorsActive, not recruiting

Intestinal CancerRecruiting

Breast CancerRecruiting

Advanced or Metastatic Solid TumorsPhase 1

Active, not recruiting

Intestinal CancerPhase 1

Recruiting

Breast CancerPhase 1

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adenocard

Astellas

Preclinical

2 2

BL-M17D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 3

Ablavar

LLantheus Medical Imaging

Preclinical

2 4

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 5

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 6

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 8

Lapatinib Plus Capecitabine

GSK

Preclinical

2 9

Midazolam Premedication

YYonsei University

Preclinical

1 10

Combination NRT

UUniversity of Alabama at Birmingham

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Advanced or Metastatic Solid Tumors

NCT06714617

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumors1 trial

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Active, not recruiting·SSystImmune Inc.·Phase 1·NCT06714617·120 enrolled

Breast Cancer1 trial

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT06503783·20 enrolled

Intestinal Cancer1 trial

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT06500052·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BL-M17D1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BL-M17D1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BL-M17D1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Baili Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSichuan Baili Pharmaceutical Co., Ltd.

BL-M17D1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Advanced or Metastatic Solid Tumors1 trial

Breast Cancer1 trial

Intestinal Cancer1 trial

References

Drug Info

Quick Facts

Related News